BAM15 (15mg) 60 capsules

Mitochondrial Uncoupler: Selective protonophore (C₁₆H₁₀F₂N₆O), ≥98% purity
AMPK Activation: 1,000-fold greater potency than metformin per unit concentration
Metabolic Research: 50+ publications since 2014, validated in Nature Communications

Manufacturer: RiboCore

Availability: In stock

SKU: RC-BAM15-15MG-60-CAPSUL

$99.00

Ship to

Shipping Method

Estimated Delivery

Price

No shipping options

Technical Specifications

Characteristic	Value
CAS Number	210302-17-3
Molecular Weight	340.29 Da
Purity	≥98% (HPLC)
Form	Capsules (15mg per capsule)

BAM15 (N5,N6-bis(2-fluorophenyl)[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine) is a synthetic small-molecule mitochondrial protonophore uncoupler that has emerged as a paradigm-shifting research tool for metabolic disease investigation since its initial characterization in 2014. Unlike classical uncouplers such as DNP and FCCP, BAM15 selectively uncouples oxidative phosphorylation in mitochondria without affecting plasma membrane potential, conferring a substantially wider therapeutic window and reduced cytotoxicity.

The compound's discovery emerged from systematic screening at the University of New South Wales and Virginia Tech to identify mitochondrial uncouplers with improved safety profiles. BAM15 demonstrates an EC50 of approximately 270 nM for mitochondrial uncoupling while maintaining cellular viability at concentrations where FCCP becomes cytotoxic. As of early 2026, BAM15 has been the subject of over 50 peer-reviewed publications spanning metabolic disease, oncology, sepsis, cardiovascular biology, neurodegeneration, and aging research.

Key Research Highlights

Research Area	Key Finding
Diet-Induced Obesity	Oral BAM15 (10-50 mg/kg daily) completely reversed HFD-induced weight gain in mice, normalizing body weight to lean controls without affecting food intake
Metabolic Performance	Identified as top-performing compound among 15 uncouplers in 2025 comparative study, with broadest effective dosing range (0.5-50 µM)
Sepsis Survival	Increased sepsis survival from 25% to 75% at 7 days; effective even with delayed treatment at 6-12 hours post-induction
Safety Profile	No effects on body temperature, no detectable tissue toxicity, normal hematological parameters across chronic dosing studies

Research Applications

Mitochondrial biology and oxidative phosphorylation coupling studies
Obesity and metabolic disease research with fat-selective mass reduction
Inflammation and immune metabolism investigation
Cardiovascular research including atherosclerosis and endothelial dysfunction
Oncology research exploiting cancer-specific metabolic vulnerabilities
Neurodegeneration and aging research with hormesis-based interventions
Sepsis and acute kidney injury protection mechanisms
Comparative pharmacology and mitochondrial uncoupler development